Novel tracer for prostate cancer improves sensitivity
A new radiotracer, FACBC, may help identify presence or absence of focal neoplastic involvement in patients with prostate cancer, according to work conducted at Emory University.
A new radiotracer, FACBC, may help identify presence or absence of focal neoplastic involvement in patients with prostate cancer, according to work conducted at Emory University. Researchers using the tracer demonstrated its uptake in both primary and metastatic prostate cancer on initial staging, as well as in recurrent cancer within the prostate bed, lymph nodes, and bone. The findings were reported in the January issue of the Journal of Nuclear Medicine.
Dr. David M. Schuster and colleagues evaluated nine patients with a recent diagnosis of prostate cancer and six with suspected recurrence. In eight of the newly diagnosed patients who underwent dynamic scanning, visual analysis correctly identified the presence or absence of focal neoplastic involvement in 40 of 48 prostate sextants. Pelvic nodal status correlated with FACBC findings in seven of nine patients and was indeterminate in two.
In all four patients with proven recurrence, researchers identified disease. In three of these patients, indium-111 ProstaScint had no significant uptake at nodal and skeletal foci.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
